Back to top
more

Pfizer (PFE)

(Delayed Data from NYSE)

$29.09 USD

29.09
25,001,151

+0.12 (0.41%)

Updated Sep 27, 2024 04:02 PM ET

After-Market: $29.09 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value F Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 18% (45 out of 251)

Industry: Large Cap Pharmaceuticals

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Voyager (VYGR) Surges on Gene Therapy Deal With Pfizer

by Zacks Equity Research

Voyager (VYGR) signs agreement with Pfizer granting the latter with rights to develop novel capsids using Voyager's proprietary technology for Pfizer's gene therapies and options for exclusive license to the capsids.

Down 9.7% in 4 Weeks, Here's Why You Should You Buy the Dip in Pfizer (PFE)

by Zacks Equity Research

Pfizer (PFE) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Top Ranked Income Stocks to Buy for October 7th

by Zacks Equity Research

OXLC, ING, PFE, and BRT made it to the Zacks Rank #1 (Strong Buy) income stocks list on October 7, 2021

Vaxart (VXRT) Starts Recruitment in Oral COVID-19 Vaccine Study

by Zacks Equity Research

Vaxart (VXRT) commences recruiting subjects in its mid-stage study for its oral vaccine tablet for COVID-19. It will begin dosing in the United States later this month.

Moderna (MRNA) Gets EMA Authorization for SpikeVax Third Dose

by Zacks Equity Research

Moderna (MRNA) gets authorization for the third dose of its COVID-19 vaccine, Spikevax, for use in immunocompromised individuals in Europe.

J&J (JNJ) Seeks FDA Authorization for COVID-19 Booster Jab

by Zacks Equity Research

J&J (JNJ) submits data to the FDA to support an authorization for the booster dose of its single-shot COVID-19 vaccine.

Ekta Bagri headshot

Biotech Stock Roundup: MRNA's Vaccine Update, GILD's CAR T Therapy Label Expansion

by Ekta Bagri

Regulatory and pipeline updates from bigwigs like Moderna (MRNA) and Gilead (GILD) have been the biotech sector's few key highlights during the past week.

Neena Mishra headshot

Should You Invest in Travel & Tourism ETFs Now?

by Neena Mishra

Travel stocks could benefit from pent-up demand as we return to normal

Tilray (TLRY) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

Investors will focus on revenue growth and other pipeline updates when Tilray (TLRY) reports first-quarter fiscal 2022 results.

RedHill (RDHL) COVID Pneumonia Drug Meets Study Goal, Stock Up

by Zacks Equity Research

Redhill's (RDHL) opaganib achieves a significant reduction in mortality in hospitalized patients with severe COVID-19 pneumonia based on new data from the phase II/III study.

Sarepta (SRPT) Begins Pivotal Study on DMD Gene Therapy

by Zacks Equity Research

Sarepta (SRPT) is developing its lead gene therapy candidate, SRP-9001, as a potential one-time treatment for DMD.

Glaxo (GSK) Eyes Nod for Triumeq Expanded Use in Pediatric HIV

by Zacks Equity Research

Glaxo (GSK) seeks approval for a new dispersible single-tablet regimen containing dolutegravir to treat children living with HIV.

Pfizer (PFE) Stock Moves -1.19%: What You Should Know

by Zacks Equity Research

In the latest trading session, Pfizer (PFE) closed at $42.42, marking a -1.19% move from the previous day.

Will Pfizer (PFE) Beat Estimates Again in Its Next Earnings Report?

by Zacks Equity Research

Pfizer (PFE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Is Pfizer (PFE) a Great Value Stock Right Now?

by Zacks Equity Research

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

BioNTech (BNTX) Begins Dosing in mRNA Cancer Vaccine Study

by Zacks Equity Research

BioNTech (BNTX) doses the first patient in a phase II study on its mRNA cancer vaccine candidate, BNT122, in patients with colorectal cancer.

3 Drugmakers in Focus After Merck's Positive COVID-19 Pill Data

by Zacks Equity Research

Here we discuss three other pharma or biotech companies with promising oral drug candidates for treating COVID-19 following Merck's (MRK) announcement of promising clinical data on its oral therapy.

Kinjel Shah headshot

Vaccine Stocks Down Following Merck's COVID-19 Pill Success

by Kinjel Shah

Stocks of several COVID-19 vaccine makers declined on Friday after Merck (MRK) released positive data for a new oral antiviral treatment for COVID-19

The Zacks Analyst Blog Highlights: Barings BDC, FirstEnergy, Pfizer and Redwood Trust

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Barings BDC, FirstEnergy, Pfizer and Redwood Trust

Sweta Jaiswal, FRM headshot

Take a Look at the Top-Performing Biotech ETFs YTD

by Sweta Jaiswal, FRM

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

Tirthankar Chakraborty headshot

4 of the Best Stocks to Counter a Volatile October

by Tirthankar Chakraborty

After the September slump, more volatility may be awaiting October, which calls for investing in risk-adjusted stocks like BARINGS BDC (BBDC), FirstEnergy (FE), Pfizer (PFE) & Redwood Trust (RWT).

The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Pfizer, Novo Nordisk and Sanofi

AstraZeneca (AZN) to Buy Full Stake in Rare Disease Drugmaker

by Zacks Equity Research

AstraZeneca (AZN) looks to buy full stake in Caelum Biosciences to sharpen its focus on rare-disease drugs.

Pfizer's (PFE) Prevnar 20 Plus Flu Vaccine Study Meets Goal

by Zacks Equity Research

Pfizer's (PFE) Prevnar 20 co-administered with a flu vaccine elicits non-inferior immunogenicity compared to administration of the vaccines one month apart in a late-stage study.

J&J (JNJ) Starts Phase III Study on RSV Vaccine in Older Adults

by Zacks Equity Research

J&J (JNJ) starts the phase III study on its RSV vaccine candidate in adults aged 60 years and above.